This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
ESC/EAS update clinical guidance on PCSK9

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force.

Publication in full

Authors

Ulf Landmesser, M. John Chapman, Jane K. Stock, Pierre Amarenco, Jill J.F. Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham, Diederick E. Grobbee, G. Kees Hovingh, Thomas F. Lüscher, Massimo F. Piepoli, Kausik K. Ray, Erik S. Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto Pinto, Lale Tokgözoğlu, Jeroen J. Bax, Alberico L Catapano on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Editorial

ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors, by  Jane K. Stock

Slide set

Video


Membership Software Powered by YourMembership  ::  Legal